#United States #New York #Class Action #Shareholders #Capricor Therapeutics

Capricor Therapeutics Faces Legal Challenges

Recently, Capricor Therapeutics, Inc. (NASDAQ: CAPR) has found itself entangled in a securities law violation lawsuit. Shareholders who bought shares during the class action date range are urged to contact The Gross Law Firm before September 15, 2025, for guidance on their rights and potential participation in the lawsuit.

Background of Allegations

The allegations against Capricor revolve around misleading communication regarding their lead cell therapy candidate, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). In the complaint, it is asserted that while Capricor made optimistic announcements about the potential approval of a Biologics License Application (BLA) for deramiocel by the U.S. Food and Drug Administration (FDA), it concealed crucial negative facts concerning the four-year safety and efficacy data from its Phase 2 HOPE-2 trial.

On July 11, 2025, Capricor publicly announced it received a Complete Response Letter (CRL) from the FDA, stating that the BLA did not satisfy the necessary proof of effectiveness and needed additional clinical information. This announcement triggered a sharp decline in the stock price, plummeting from $11.40 per share on July 10 to $7.64 on the following day.

Details of the Class Period

The specified class period for shareholders to consider is from October 9, 2024, to July 10, 2025. Those who acquired shares within this window are encouraged to reach out and secure their eligibility for potential compensation should the lawsuit progress favorably. Registration for the class action is free and comes with no obligations.

Important Deadlines

Shareholders keen on pursuing claims need to act promptly, with the lead plaintiff registration deadline set for September 15, 2025. Participation in the case is voluntary and does not hinge upon one’s acceptance of a lead plaintiff role. Once registered, shareholders will be incorporated into a monitoring program to receive updates on the case’s development.

Why Choose The Gross Law Firm?

The Gross Law Firm is a well-respected national entity specializing in class action laws, focusing on protecting investors' rights. Their mission centers around ensuring that companies adhere to ethical business practices and are held accountable in instances of misinformation or fraud that affects stakeholders. The firm’s professionals are equipped to assist investors who have suffered financial loss due to misleading statements or omissions of essential information by corporations.

In essence, this situation underscores the importance of vigilance among investors in maintaining awareness of the firms they are involved with and advocating for transparency and integrity in the financial markets.

Shareholders of Capricor Therapeutics, therefore, should not hesitate to register their interest in the ongoing claims as the deadline approaches. Continuous updates throughout the case will ensure investors remain informed about their stakes in this developing legal battle.